2023年4月13日

分享這篇文章提供的新聞分享本文奧爾巴尼,紐約2023年4月13日——碼Pharmatech,計算藥物發現公司專業從事感應距離,今天宣布任命羅伯特·沙利文博士的藥用化學。擁有超過20年的經驗在這個領域,沙利文博士擁有專業知識在小分子,PROTACs,多肽、寡核苷酸。沙利文博士曾擔任BioTheryX臨床前開發的主管,他發揮了關鍵作用在創建Cereblon綁定庫和定向研究,導致20多頒發專利。這些專利涵蓋範圍廣泛的小分子(分子膠水)和PROTACs。BioTheryX之前,沙利文博士舉行執行NovoMedix藥物開發主管的位置,在那裏他導致了藥物發現工作候選人進入IND-enabling antifibrotic和乳腺癌發展研究。在他傑出的職業生涯中,沙利文博士擔任領導職位在PYC療法,主角,糊精製藥、製藥Kemia,神經內分泌的,信號。的先驅科學家在高通量平行合成技術和組合化學,他合著了20同行評議的出版物。沙利文博士獲得化學學士學位的加州大學聖芭芭拉分校和加州大學的化學博士學位,歐文。“我們很高興歡迎羅伯特·沙利文博士碼Pharmatech團隊,“邢切博士說,首席執行官碼Pharmatech。 "His extensive experience in targeted protein degrader discovery is invaluable to us. Dr. Sullivan's expertise will enhance YDS's ability to bridge the gap between computational scientists, biologists, and chemists, fostering more efficient integrated research. As a result, our computational platform for rationalizing drug discovery of protein degraders will see accelerated development. "I am truly excited to join such a dynamic organization like YDS Pharmatech. YDS's unique platform of combining AI and biophysics simulations to help drive drug discovery and development are second to none," said Robert Sullivan, Ph.D., Head of Medicinal Chemistry. "I look forward to working with the YDS team and it's partners to create drugs that address unmet medical needs." Dr. Sullivan's appointment as Head of Medicinal Chemistry bolsters YDS Pharmatech's dedication to remaining at the cutting edge of combining AI and biophysics simulations for induced proximity drug discovery. This state-of-the-art approach ensures that YDS Pharmatech stays at the forefront of innovation, while providing valuable support to partner companies collaborating with YDS to create groundbreaking medicines that address unmet medical needs. About YDS Pharmatech YDS Pharmatech, Inc. is a computational drug discovery company dedicated to developing cutting-edge computational platforms for multispecific drugs. Utilizing AI-accelerated enhanced sampling molecular dynamics simulations, the company examines ternary complex interactions, thermodynamics, and kinetics to advance induced proximity studies and transform degrader discovery from serendipitous to rational design. YDS Pharmatech currently specializes in PROTACs and molecular glue protein degraders. Their interdisciplinary team of scientists is committed to accelerating their collaborators' efforts in pioneering innovative treatments for a diverse range of diseases. SOURCE YDS Pharmatech, Inc.